Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALON extension study of brolucizumab treat-to-control up to 20-week intervals in neovascular age-related macular degeneration
NL-OMON55258Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brolucizumab in exudative macular degeneration, sponsored by Novartis. Primary endpoints: Duration of the last interval with no disease activity up to Week 56 and Change in best corrected visual acuity at Week 52 and Week 56. Started Jan 2021; status: active, not recruiting.
02
Drugs
brolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON55258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55258.